Published in Biochem Pharmacol on November 15, 1982
The plasma protein binding of basic drugs. Br J Clin Pharmacol (1986) 1.49
Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol (1993) 0.96
Development of an affinity silica monolith containing alpha1-acid glycoprotein for chiral separations. J Chromatogr A (2007) 0.95
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1991) 0.94
Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother (2008) 0.88
pH-dependence of warfarin binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1993) 0.84
Characterization of discrete classes of binding sites of human serum albumin by application of thermodynamic principles. Biochem J (1994) 0.83
Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol (2003) 0.81
Analysis of free drug fractions in serum by ultrafast affinity extraction and two-dimensional affinity chromatography using α1-acid glycoprotein microcolumns. J Chromatogr A (2016) 0.77
Characterization of binding of raltegravir to plasma proteins. Antimicrob Agents Chemother (2013) 0.76
Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. Eur J Clin Pharmacol (2012) 0.76
On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography. Anal Bioanal Chem (2016) 0.75
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol (1982) 1.65
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther (2008) 1.56
Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci (1984) 1.54
Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res (2010) 1.50
Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf (1998) 1.39
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res (1999) 1.26
Clofibrate and enzymatic induction in man. Int J Clin Pharmacol Biopharm (1978) 1.18
Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem (1985) 1.11
Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet (1994) 1.11
Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs (1996) 1.08
[Sinus bradycardia and sinoauricular block induced by carbamazepine]. Presse Med (1983) 1.07
Pharmacological postconditioning with the phytoestrogen genistein. J Mol Cell Cardiol (2006) 1.07
Influence of sex on drug kinetics in man. Clin Pharmacokinet (1977) 1.06
Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death Differ (2006) 1.05
The distribution of bound propranolol between the different human serum proteins. Mol Pharmacol (1980) 1.05
Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem (2000) 1.05
Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol (1984) 1.04
Diseases and drug protein binding. Clin Pharmacokinet (1978) 1.01
Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React (1996) 1.00
Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin. Clin Pharmacol Ther (1986) 1.00
Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters. Eur J Clin Pharmacol (1974) 0.98
Critical risk/benefit analysis of pefloxacine use in children under 15 years--the problem of arthralgias. Int J Clin Pharmacol Ther Toxicol (1987) 0.97
Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol (1998) 0.97
Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br J Clin Pharmacol (2005) 0.96
Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol (1993) 0.96
Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam Clin Pharmacol (1999) 0.95
Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther Drug Monit (1983) 0.94
pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid). Biochem J (1991) 0.94
A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm (1987) 0.93
Isolation and characterization of a murine resident liver stem cell. Cell Death Differ (2007) 0.92
Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol (1985) 0.92
Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit (1988) 0.92
Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol (1998) 0.92
The binding of aryl carboxylic acid derivatives to human serum albumin--a structure-activity study. Biochem Pharmacol (1984) 0.92
In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res (2001) 0.92
In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs (2000) 0.91
New insights into the second generation antihistamines. Drugs (2001) 0.91
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet (1990) 0.91
Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res (1996) 0.91
Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol (2004) 0.91
Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Life Sci (1998) 0.89
Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett (2001) 0.89
Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study. Br J Clin Pharmacol (2001) 0.89
Binding of 8-methoxypsoralen to human serum proteins and red blood cells. Br J Dermatol (1987) 0.89
Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol (2000) 0.88
Ultrafast and whole-body cooling with total liquid ventilation induces favorable neurological and cardiac outcomes after cardiac arrest in rabbits. Circulation (2011) 0.88
Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther (1998) 0.88
Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS (1999) 0.88
Separation procedures used to reveal and follow drug-protein binding. J Chromatogr (1990) 0.87
Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs (2003) 0.87
Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res (1983) 0.87
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia (2009) 0.87
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol (1987) 0.87
A GLC method for estimation of chlorophenoxyisobutyric acid in plasma. Pharmacokinetics of a single oral dose of clofibrate in man. Eur J Clin Pharmacol (1975) 0.87
In vitro studies on the distribution of probucol among human plasma lipoproteins. Mol Pharmacol (1984) 0.87
Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radic Biol Med (1998) 0.87
Dehydroepiandrosterone and alpha-estradiol limit the functional alterations of rat brain mitochondria submitted to different experimental stresses. Neuroscience (2002) 0.86
Serotonin enhances the beta-adrenergic response in rat brain cortical slices. Eur J Pharmacol (1992) 0.86
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem (2000) 0.86
Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol (1996) 0.86
Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes. Biochem Pharmacol (1992) 0.86
Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol (1993) 0.86
Effects of trimetazidine on lipid peroxidation and phosphorus metabolites during cold storage and reperfusion of isolated perfused rat kidneys. J Pharmacol Exp Ther (1998) 0.86
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol (2011) 0.86
[Thrombopenia caused by isoniazid]. Therapie (1994) 0.85
Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins. Biochem Pharmacol (1982) 0.85
Glucocorticoids decrease cytochrome c oxidase activity of isolated rat kidney mitochondria. FEBS Lett (1998) 0.85
Study of the expression of the genetic variants of human alpha1-acid glycoprotein in healthy subjects using isoelectric focusing and immunoblotting. J Chromatogr B Biomed Sci Appl (1998) 0.85
Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol (1973) 0.85
In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res (1986) 0.85